Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

被引：0
|
作者：
Touzeau, Cyrille
Moreau, Philippe
Perrot, Aurore
Hulin, Cyrille
Dib, Mamoun
Tiab, Mourad
Caillot, Denis
Facon, Thierry
Leleu, Xavier
van de Donk, Niels W. C. J.
Broijl, Annemiek
Zweegman, Sonja
Levin, Mark-David
Delforge, Michel
Pei, Lixia
Vanquickelberghe, Veronique
De Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Sonneveld, Pieter
机构：
[1] Ctr Hosp Univ, Nantes, France
[2] Univ Hosp Hotel Dieu, Hematol, Nantes, France
[3] Univ Canc Inst IUCT, Hematol Dept, Toulouse, France
[4] Univ Hosp Bordeaux, Dept Hematol, Hop Haut Leveque, Pessac, France
[5] CHRU, Hop Bocage, Angers, France
[6] CHD Vendee, La Roche Sur Yon, France
[7] CHU Dijon, Hop Bocage, Dijon, France
[8] Univ Lille, Serv Malad Sang, CHU Lille, Lille, France
[9] CHU Poitiers, Hop Miletrie, Poitiers, France
[10] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[11] Erasmus MC, Canc Inst, Rotterdam, Netherlands
[12] Albert Schweitzer Hosp, Dordrecht, Netherlands
[13] Univ Ziekenhuizen Leuven, Leuven, Belgium
[14] Janssen Res & Dev LLC, Raritan, NJ USA
[15] Janssen Res & Dev, Beerse, Belgium
[16] Janssen Res & Dev LLC, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8538
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
    Dimopoulos, Meletios A.
    Sonneveld, Pieter
    Rodriguez-Otero, Paula
    Quach, Hang
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    Nijhof, Inger S.
    van de Donk, Niels W. C. J.
    Katodritou, Eirini
    Schjesvold, Fredrik
    Balari, Anna Sureda
    Rosinol, Laura
    Delforge, Michel
    Roeloffzen, Wilfried
    Driessen, Christoph
    Vangsted, Annette
    Einsele, Hermann
    Spencer, Andrew
    Hajek, Roman
    Jurczyszyn, Artur
    Lonergan, Sarah
    Liu, Yanfang
    Wang, Jianping
    Vieyra, Diego
    van Brummelen, Emilie M. J.
    Vanquickelberghe, Veronique
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Blade, Joan
    Boccadoro, Mario
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S547 - S548
  • [42] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Bobba, Padma
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [43] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson Jr, Larry D.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
  • [44] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [45] Superiority of Triple Combination Bortezomib plus Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide plus Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Maiolino, Angelo
    Sousa, Lais
    Nunes, Renata Ferreira Marques
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Magalhaes, Andre
    Leao, Danielle
    Pinto Neto, Jorge Vaz
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emmanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Kutner, Jose Mauro
    Colli, Gilberto
    Santucci, Rodrigo
    Magalhaes, Roberto Jose Pessoa
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [46] Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
    Moreau, Philippe
    Hulin, Cyrille
    Perrot, Aurore
    Arnulf, Bertrand
    Belhadj, Karim
    Benboubker, Lotfi
    Zweegman, Sonja
    Caillon, Helene
    Caillot, Denis
    Avet-Loiseau, Herve
    Delforge, Michel
    Dejoie, Thomas
    Facon, Thierry
    Sonntag, Cecile
    Fontan, Jean
    Mohty, Mohamad
    Jie, Kon-Siong
    Karlin, Lionel
    Kuhnowski, Frederique
    Lambert, Jerome
    Leleu, Xavier
    Macro, Margaret
    Orsini-Piocelle, Frederique
    Roussel, Murielle
    Colella, Jean Marc Schiano de
    van de Donk, Niels W. C. J.
    Wuilleme, Soraya
    Broijl, Annemiek
    Touzeau, Cyrille
    Tiab, Mourad
    Marolleau, Jean-Pierre
    Meuleman, Nathalie
    Vekemans, Marie-Christiane
    Westerman, Matthijs
    Klein, Saskia K.
    Levin, Mark-David
    Offner, Fritz
    Escoffre-Barbe, Martine
    Eveillard, Jean-Richard
    Garidi, Reda
    Hua, Winnie
    Wang, Jianping
    Tuozzo, Alba
    de Boer, Carla
    Rowe, Melissa
    Vanquickelberghe, Veronique
    Carson, Robin
    Vermeulen, Jessica
    Corre, Jill
    Sonneveld, Pieter
    LANCET ONCOLOGY, 2024, 25 (08): : 1003 - 1014
  • [47] Progression Free Survival (PFS) Analysis of Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients
    Crusoe, Edvan De Queiroz
    Leal, Joanna
    Salvino, Marco Aurelio
    Lucas, Larissa Ferreira
    Santos, Juliana Andrade
    Santos, Herbert Henrique de Melo
    Almeida, Alessandro de M.
    Santos, Allan de souza
    Chaves, Marcos
    Santos, Mariane Melo
    Silva, Sarah Queiroz
    Vieira, Lucas de Oliveira
    Fonseca, Cleverson Alves
    Adorno, Elisangela
    Hungria, Vania
    Arruda, Maria da Gloria B.
    BLOOD, 2021, 138
  • [48] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Kazuhito Suzuki
    Nobuhiro Tsukada
    Noriko Nishimura
    Yasuyuki Nagata
    Kiyoshi Okazuka
    Yuko Mishima
    Masahiro Yokoyama
    Kaichi Nishiwaki
    Tadao Ishida
    Shingo Yano
    Yasuhito Terui
    Kenshi Suzuki
    International Journal of Hematology, 2020, 111 : 103 - 111
  • [49] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [50] Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.
    Rodriguez, Cesar
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Chari, Ajai
    Silbermann, Rebecca Wang
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Jakubowiak, Andrzej J.
    Orlowski, Robert Z.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345